Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
21.91
-1.40 (-6.01%)
At close: Jun 5, 2026, 4:00 PM EDT
22.34
+0.43 (1.96%)
After-hours: Jun 5, 2026, 7:57 PM EDT

Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $52.05. The average 1-year stock price forecast is 137.56% higher than the current stock price, while the lowest is $25 (+14.10%) and the highest is $96 (+338.16%).

Price Target: $52.05 (+137.56%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$25$52.05$48$96
Change+14.10%+137.56%+119.08%+338.16%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy151514131312
Buy555555
Hold111222
Sell000000
Strong Sell000000
Total212120202019

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Buy
Maintains
$74$72
BuyMaintains$74$72+228.62%May 23, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
$84$96
BuyReiterates$84$96+338.16%May 21, 2026
Evercore ISI
Evercore ISI
Buy
Maintains
$34$33
BuyMaintains$34$33+50.62%May 11, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$79
BuyMaintains$79+260.57%May 11, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$50
BuyReiterates$50+128.21%May 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
741.43M
from 673.00M
Increased by 10.17%
Revenue Next Year
983.59M
from 741.43M
Increased by 32.66%
EPS This Year
-4.24
from -5.83
EPS Next Year
0.97
from -4.24
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
351.41M363.33M434.00M560.00M673.00M741.43M
Revenue Growth
29.66%3.39%19.45%29.03%20.18%10.17%
Gross Profit
-161.76M-370.78M-259.00M-215.00M-186.00M603.53M
Gross Margin
-46.03%-102.05%-59.68%-38.39%-27.64%81.40%
Operating Income
-381.74M-648.92M-569.00M-536.00M-535.00M-441.57M
Net Income
-454.03M-707.42M-607.00M-569.00M-575.00M-475.43M
EPS
-----5.83-4.24
Free Cash Flow
-244.82M-370.58M-312.54M-207.00M-251.13M358.00M
No. Analysts
-----17
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High769.1M
Avg741.4M
Low714.1M

Revenue Growth

Revenue Growth202620272028
High
14.3%
Avg
10.2%
Low
6.1%

EPS Forecast

EPS202620272028
High-
Avg-4.24
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-